Same but different: Unique cancer traits key to targeted therapies
Melbourne researchers have discovered that the key to personalised therapies for some types of lung…
Browsing: Lung Cancer
Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients
Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a…
Video assisted lung surgery reduces complications and hospital stays
Video-assisted thoracic surgery is associated with lower in-hospital complications and shorter length of stay compared…
Updated results on genomically tailored therapy for lung cancer patients
Selpercatinib was granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration in 2018…
Preclinical research suggests anti-cancer effect of keto diet
It’s well known that keeping blood glucose levels in check can help individuals avoid or…
ASCO 2019: The eight biggest stories on anticancer agents
Here is ecancer’s speedy recap on the presentations from the 2019 American Society of Clinical…
ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung cancer
A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients…
ASCO 2019: NRG oncology trial of metformin for non-small cell lung cancer
Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients,…
ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…
ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response…